October 2010 in “International journal of radiation oncology, biology, physics” Two cycles of ABVD chemotherapy followed by 20 Gy radiotherapy is the new standard for early-stage Hodgkin lymphoma due to lower toxicity and similar effectiveness.
December 2022 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature”
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
11 citations
,
January 2021 in “Breast Care” Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
December 2024 in “Dermatologic Surgery”
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
2 citations
,
February 2023 in “F&S Reports” Elagolix did not effectively treat polycystic ovary syndrome.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
Topical GT20029 effectively promotes hair regrowth and is well-tolerated.
8 citations
,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
November 2010 in “Value in Health” Using a call center to collect data in a trial for eye disease in diabetics led to high response rates and very little missing information.
July 2024 in “Journal of Investigative Dermatology” 36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
1 citations
,
September 2007 in “Neuromuscular disorders” The treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may improve muscle strength in children with SMA without significant side effects.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.